#ASCO22: A small China biotech player makes its debut at ASCO with promising data on its GPRC5D multiple myeloma drug
With all the headlines jumping out of ASCO this year, you’d be forgiven for overlooking the upbeat data coming from a low-profile Chinese biotech. But it’s worth a close second look.
Shanghai-based OriCell, a private player, has highlighted a round of promising Phase I results for its personalized GPRC5D-directed CAR-T OriCAR-017. Directed at a small group of treatment-resistant patients suffering from multiple myeloma, the biotech reported a 100% overall response rate with 60% stringent CRs.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.